PMC8649083_01
Change in FVC % predicted by time. Time 0 is initiation of antifibrotic therapy.
gr1.jpg
PMC8649083_01_gr1.jpg
fig1
Nintedanib was added when the patient experienced worsening of symptoms, progression of fibrosis by CT chest, increasing oxygen requirement from 2LPM to 6LPM with exertion, and decline in relative forced vital capacity (FVC) % predicted by 27.2% over 12 months despite antigen removal and an IS regimen of mycophenolate 1.5g twice daily and prednisone 10-30mg daily (Fig. 1).
PMC8649083_02
PMC8649083_03
PMC8649083_04
PMC8649083_05